


**Table 1A: Prior month HCT vs. current EPO dose, 2003**  
**HD patients only**


Current month EPO dose	HCT in prior month			Total
	≤33	>33 and ≤36	>36	
<b>Number of patient months</b>				
Less Than 2,001 Units per Session	177,597	146,847	303,462	627,906
2,001 - 12,000 Units per Session	437,231	503,422	599,602	1,540,255
More Than 12,000 Units per Session	172,834	72,414	54,114	299,362
<b>Total</b>	<b>787,662</b>	<b>722,683</b>	<b>957,178</b>	<b>2,467,523</b>
<b>Percent of total</b>				
Less Than 2,001 Units per Session	7%	6%	12%	25%
2,001 - 12,000 Units per Session	18%	20%	24%	62%
More Than 12,000 Units per Session	7%	3%	2%	12%
<b>Total</b>	<b>32%</b>	<b>29%</b>	<b>39%</b>	<b>100%</b>
<b>Percent of row</b>				
Less Than 2,001 Units per Session	28%	23%	48%	100%
2,001 - 12,000 Units per Session	28%	33%	39%	100%
More Than 12,000 Units per Session	58%	24%	18%	100%
<b>Total</b>	<b>32%</b>	<b>29%</b>	<b>39%</b>	<b>100%</b>
<b>Percent of column</b>				
Less Than 2,001 Units per Session	23%	20%	32%	25%
2,001 - 12,000 Units per Session	56%	70%	63%	62%
More Than 12,000 Units per Session	22%	10%	6%	12%
<b>Total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>

**Relation of Hct to EPO dose**





**Table 1B: Partial range of possible values for EPO dose-response variable**  
**Units of EPO per session per g/dL of hemoglobin**

Dose	Hct / Hg								
	Hct=24 Hb=8g/dL	Hct=27 Hb=9g/dL	Hct=30 Hb=10g/dL	Hct=33 Hb=11g/dL	Hct=36 Hb=12g/dL	Hct=39 Hb=13g/dL	Hct=42 Hb=14g/dL	Hct=45 Hb=15g/dL	
1k units	125	111	100	91	83	77	71	67	
2k units	250	222	200	182	167	154	143	133	
3k units	375	333	300	273	250	231	214	200	
4k units	500	444	400	364	333	308	286	267	
5k units	625	556	500	455	417	385	357	333	
6k units	750	667	600	545	500	462	429	400	
7k units	875	778	700	636	583	538	500	467	
8k units	1,000	889	800	727	667	615	571	533	
9k units	1,125	1,000	900	818	750	692	643	600	
10k units	1,250	1,111	1,000	909	833	769	714	667	
11k units	1,375	1,222	1,100	1,000	917	846	786	733	
12k units	1,500	1,333	1,200	1,091	1,000	923	857	800	
13k units	1,625	1,444	1,300	1,182	1,083	1,000	929	867	
14k units	1,750	1,556	1,400	1,273	1,167	1,077	1,000	933	
15k units	1,875	1,667	1,500	1,364	1,250	1,154	1,071	1,000	
16k units	2,000	1,778	1,600	1,455	1,333	1,231	1,143	1,067	
17k units	2,125	1,889	1,700	1,545	1,417	1,308	1,214	1,133	
18k units	2,250	2,000	1,800	1,636	1,500	1,385	1,286	1,200	
19k units	2,375	2,111	1,900	1,727	1,583	1,462	1,357	1,267	
20k units	2,500	2,222	2,000	1,818	1,667	1,538	1,429	1,333	
21k units	2,625	2,333	2,100	1,909	1,750	1,615	1,500	1,400	
22k units	2,750	2,444	2,200	2,000	1,833	1,692	1,571	1,467	
23k units	2,875	2,556	2,300	2,091	1,917	1,769	1,643	1,533	
24k units	3,000	2,667	2,400	2,182	2,000	1,846	1,714	1,600	



**Table 1B: Partial range of possible values for EPO dose-response variable**  
**Units of EPO per session per g/dL of hemoglobin**



**Table 2A: Alternative Models 1 - 5**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	<b>Model</b>				
	<b>Model 1</b>	<b>Model 2</b>	<b>Model 3</b>	<b>Model 4</b>	<b>Model 5</b>
Model form	Log	Log	Log	Log	Log
Base CM model	X	X	X	X	X
Prior EPO Response (1 to 3 months)**		X		X	X
Prior EPO Response (6 to 8 months)**			X		
Hct (prior month)				X	
Facility					X
Patient months	1,943,552	1,943,552	1,943,552	1,943,552	1,943,552
Percent of total used in analysis	79%	79%	79%	79%	79%
R-squared	0.0743	0.7588	0.2795	0.8874	0.8175
Mean (Actual)	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37
Std. Dev. Predicted	\$22.24	\$71.08	\$43.14	\$76.87	\$73.78
Std. Dev. Actual	\$81.60	\$81.60	\$81.60	\$81.60	\$81.60
Correlation with prior month prediction error					
t-1	0.73	0.49	0.66	0.51	0.47
t-2	0.62	0.29	0.49	0.37	0.25
t-3	0.57	0.20	0.38	0.29	0.16
t-4	0.53	0.22	0.29	0.28	0.18
t-5	0.50	0.23	0.21	0.27	0.18
t-6	0.48	0.21	0.12	0.26	0.17
t-7	0.45	0.19	0.08	0.23	0.15
t-8	0.43	0.18	0.08	0.22	0.14
t-9	0.42	0.18	0.13	0.22	0.14
t-10	0.40	0.16	0.13	0.20	0.13
t-11	0.38	0.15	0.12	0.18	0.11
Percentile distribution of prediction error***					
Std Dev	\$77.73	\$65.18	\$71.65	\$66.51	\$63.53
Minimum	-\$300.63	-\$734.71	-\$771.75	-\$1,105.94	-\$1,184.01
1st	-\$82.08	-\$161.84	-\$107.81	-\$178.25	-\$162.92
5th	-\$56.66	-\$55.93	-\$56.96	-\$55.15	-\$55.42
25th	-\$24.44	-\$16.44	-\$21.08	-\$15.70	-\$15.88
50th	\$4.46	\$6.68	\$5.45	\$6.74	\$5.99
75th	\$46.18	\$35.63	\$42.27	\$34.43	\$33.37
95th	\$152.52	\$97.07	\$130.95	\$92.53	\$91.42
99th	\$288.68	\$181.33	\$244.15	\$176.01	\$168.61
Maximum	\$6,929.15	\$6,927.98	\$6,911.27	\$6,939.45	\$6,879.61

**Notes**

\* See Note 1.

\*\* See Note 2.

\*\*\* See Note 3.

**Table 2B: Models 1 - 5: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier									
		Model 1	Model 2	Model 3	Model 4	Model 5					
<b>Model parameters</b>											
Model form		Log	Log	Log	Log	Log					
Base CM model		X	X	X	X	X					
EPO Response (1 to 3 months)			X				X			X	
EPO Response (6 to 8 months)				X							
Hct (prior month)							X				
Facility										X	
<b>Independent Variables</b>											
Prior EPO dose-response			<b>1.396</b>		<b>1.287</b>		<b>1.374</b>		<b>1.384</b>		
Hematocrit (prior month)							0.967				
<b>Age group</b>											
<18 years	0.11%	<b>0.841</b>	<b>0.936</b>	11%	<b>0.950</b>	13%	<b>0.915</b>	9%	<b>1.196</b>	42%	
18-44	11.62%	1.014	1.002	-1%	1.025	1%	0.997	-2%	1.002	-1%	
45-59	22.68%	1.020	0.998	-2%	1.016	0%	0.997	-2%	0.997	-2%	
60-69	23.78%	1.035	1.010	-2%	1.020	-1%	1.009	-3%	1.009	-3%	
70-79 (ref)	27.54%	1.000	1.000		1.000		1.000		1.000		
80+	14.26%	0.955	0.983	3%	0.974	2%	0.983	3%	0.980	3%	
Female	47.53%	<b>1.178</b>	<b>1.063</b>	-10%	<b>1.074</b>	-9%	<b>1.062</b>	-10%	<b>1.066</b>	-10%	
Female & age 18-44	4.67%	<b>1.149</b>	1.027	-11%	1.046	-9%	1.026	-11%	1.030	-10%	
<b>Race</b>											
White (ref)	54.96%	1.000	1.000		1.000		1.000		1.000		
Native American	1.43%	0.975	0.969	-1%	0.962	-1%	0.982	1%	1.008	3%	
Asian	2.38%	1.005	0.983	-2%	0.979	-3%	0.979	-3%	0.987	-2%	
Black	36.96%	<b>1.055</b>	<b>1.130</b>	7%	<b>1.138</b>	8%	<b>1.131</b>	7%	<b>1.100</b>	4%	
Pacific Islander	0.84%	<b>0.880</b>	<b>0.928</b>	5%	<b>0.918</b>	4%	<b>0.927</b>	5%	0.993	13%	
Other	3.30%	1.004	1.000	0%	1.000	0%	1.006	0%	1.016	1%	
Unknown	0.13%	1.022	<b>1.086</b>	6%	<b>1.081</b>	6%	<b>1.085</b>	6%	1.011	-1%	

**Table 2B: Models 1 - 5: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier								
		Model 1	Model 2	Model 3	Model 4	Model 5				
<b>Model parameters</b>										
Model form		Log	Log		Log		Log		Log	
Base CM model		X	X		X		X		X	
EPO Response (1 to 3 months)			X				X		X	
EPO Response (6 to 8 months)					X					
Hct (prior month)							X			
Facility										X
<b>Hispanic</b>										
No (ref)	13.14%	1.000	1.000		1.000		1.000		1.000	
Yes	0.35%	<b>0.908</b>	0.995	10%	0.980	8%	0.996	10%	1.001	10%
Unknown		<b>1.069</b>	1.040	-3%	1.049	-2%	1.039	-3%	1.016	-5%
<b>Duration of RRT</b>										
Starting month	1.14%	<b>1.138</b>	<b>1.576</b>	39%	<b>1.546</b>	36%	<b>1.592</b>	40%	<b>1.589</b>	40%
Month 1	1.66%	<b>1.456</b>	<b>1.205</b>	-17%	<b>1.269</b>	-13%	<b>1.149</b>	-21%	<b>1.212</b>	-17%
Month 2	1.84%	<b>1.656</b>	<b>1.173</b>	-29%	<b>1.348</b>	-19%	<b>1.118</b>	-33%	<b>1.177</b>	-29%
Month 3	2.24%	<b>1.472</b>	<b>1.093</b>	-26%	<b>1.228</b>	-17%	<b>1.099</b>	-25%	<b>1.097</b>	-25%
Month 4	2.11%	<b>1.294</b>	1.007	-22%	<b>1.116</b>	-14%	1.046	-19%	1.010	-22%
Month 5	2.13%	<b>1.231</b>	1.001	-19%	<b>1.059</b>	-14%	1.045	-15%	1.004	-18%
Month 6	2.00%	<b>1.203</b>	1.021	-15%	0.985	-18%	<b>1.053</b>	-12%	1.023	-15%
Month 7	2.02%	<b>1.163</b>	1.025	-12%	<b>0.939</b>	-19%	1.048	-10%	1.025	-12%
Month 8	1.93%	<b>1.102</b>	1.000	-9%	<b>0.909</b>	-17%	1.021	-7%	1.001	-9%
Month 9	1.87%	<b>1.071</b>	0.991	-7%	<b>0.896</b>	-16%	1.011	-6%	0.991	-7%
Months 10-12	5.52%	1.045	0.995	-5%	<b>0.930</b>	-11%	1.007	-4%	0.994	-5%
Year 2	19.02%	1.006	0.986	-2%	0.966	-4%	0.988	-2%	0.983	-2%
Year 3	15.28%	0.996	0.991	0%	0.985	-1%	0.991	0%	0.989	-1%
Year 4+ (ref)	41.26%	1.000	1.000		1.000		1.000		1.000	

**Table 2B: Models 1 - 5: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier																		
		Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8	Model 9	Model 10									
<b>Model parameters</b>																				
Model form		Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log	Log
Base CM model		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
EPO Response (1 to 3 months)			X					X					X					X		
EPO Response (6 to 8 months)					X															
Hct (prior month)								X												
Facility																				X
<b>Body size measures</b>																				
Body surface area		1.033	1.012	-2%	1.018	-1%	1.012	-2%	1.014	-2%										
Body mass index																				
<18.5	4.36%	0.983	0.988	0%	0.990	1%	0.986	0%	0.992	1%										
≥18.5 (ref)		1.000	1.000		1.000		1.000		1.000											
<b>Laboratory values</b>																				
Hematocrit at start of RRT		0.979	0.995	2%	0.992	1%	0.996	2%	0.995	2%										
<b>Behavioral measures</b>																				
Inability to ambulate	2.60%	<b>1.051</b>	1.007	-4%	1.018	-3%	1.006	-4%	1.017	-3%										
Inability to transfer	0.74%	0.955	0.959	0%	0.957	0%	0.956	0%	0.970	2%										
Tobacco use	5.31%	<b>0.933</b>	0.978	5%	0.972	4%	0.978	5%	0.988	6%										
Alcohol Dependence	4.23%	<b>1.050</b>	1.004	-4%	1.017	-3%	1.004	-4%	1.000	-5%										
Drug Dependence	1.79%	<b>1.116</b>	1.020	-9%	1.041	-7%	1.021	-8%	1.025	-8%										
<b>Comorbid Conditions</b>																				
Congestive Heart Failure	28.12%	1.039	1.001	-4%	0.998	-4%	1.005	-3%	1.001	-4%										
Ischemic Heart Disease	25.71%	0.994	0.999	1%	0.997	0%	1.001	1%	0.998	0%										
Peripheral Vascular Disease	26.71%	1.030	1.005	-2%	1.004	-3%	1.010	-2%	1.003	-3%										
Cardiac Dysrhythmias	20.79%	1.044	1.006	-4%	1.010	-3%	1.008	-3%	1.006	-4%										
Cerebrovascular Disease	19.00%	<b>1.055</b>	1.012	-4%	1.018	-4%	1.015	-4%	1.008	-4%										
COPD	17.86%	1.050	1.011	-4%	1.020	-3%	1.012	-4%	1.011	-4%										
Diabetes (1° or Contributing)	17.13%	0.989	0.999	1%	1.000	1%	0.999	1%	1.002	1%										
Cardiac Arrest	1.58%	<b>1.107</b>	1.021	-8%	<b>1.053</b>	-5%	1.015	-8%	1.020	-8%										
Pericarditis	1.23%	<b>1.198</b>	1.018	-15%	<b>1.062</b>	-11%	1.016	-15%	1.010	-16%										

**Table 2B: Models 1 - 5: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

Model parameters	Freq.**	Multiplier								
		Model 1	Model 2	Model 3	Model 4	Model 5				
Model form		Log	Log	Log	Log	Log				
Base CM model		X	X	X	X	X				
EPO Response (1 to 3 months)			X				X		X	
EPO Response (6 to 8 months)				X						
Hct (prior month)							X			
Facility										X
Other infections	20.31%	<b>1.057</b>	1.012	-4%	1.035	-2%	1.012	-4%	1.013	-4%
Septicemia/Shock	12.44%	<b>1.164</b>	1.025	-12%	<b>1.088</b>	-7%	1.024	-12%	1.029	-12%
Other Hepatitis	12.27%	0.951	0.993	4%	0.987	4%	0.994	4%	0.998	5%
Hepatitis B	3.09%	1.027	1.021	-1%	1.022	0%	1.019	-1%	0.998	-3%
AIDS	1.25%	0.995	1.001	1%	1.011	2%	0.997	0%	1.023	3%
Aspir. & Bact. Pneumonias	1.99%	<b>1.128</b>	1.003	-11%	<b>1.070</b>	-5%	0.999	-11%	1.003	-11%
Major respiratory disease	1.28%	<b>1.161</b>	1.022	-12%	<b>1.084</b>	-7%	1.019	-12%	1.020	-12%
HIV Positive Status	0.97%	<b>1.153</b>	1.024	-11%	1.048	-9%	1.020	-12%	1.019	-12%
Opportunistic Infections	0.67%	<b>1.206</b>	1.014	-16%	<b>1.099</b>	-9%	1.005	-17%	1.019	-15%
GI Ulcer - no hemorrhage	3.13%	<b>1.132</b>	1.030	-9%	<b>1.072</b>	-5%	1.028	-9%	1.030	-9%
Hereditary Hemolytic Anemias	2.11%	<b>1.107</b>	0.991	-11%	1.020	-8%	0.984	-11%	1.003	-9%
GI Tract Bleeding	1.99%	<b>1.265</b>	1.044	-18%	<b>1.139</b>	-10%	1.037	-18%	1.044	-18%
Acquired Hemolytic Anemias	1.42%	<b>1.087</b>	0.997	-8%	1.023	-6%	0.993	-9%	1.017	-6%
Sickle-Cell Anemia	0.37%	<b>1.226</b>	1.011	-18%	<b>1.054</b>	-14%	1.000	-18%	1.017	-17%
Esophageal Varices	0.19%	<b>1.367</b>	1.019	-25%	<b>1.129</b>	-17%	0.997	-27%	1.034	-24%
Other Anemias	0.00%	<b>2.703</b>	<b>1.257</b>	-53%	<b>1.446</b>	-47%	<b>1.259</b>	-53%	<b>1.284</b>	-53%
Breast & Other Cancers	5.81%	<b>1.099</b>	1.036	-6%	<b>1.055</b>	-4%	1.034	-6%	1.031	-6%
Metastatic Cancers	1.09%	<b>1.142</b>	1.024	-10%	<b>1.063</b>	-7%	1.019	-11%	1.023	-10%
Lung & Severe Cancers	1.02%	<b>1.122</b>	1.022	-9%	<b>1.056</b>	-6%	1.016	-9%	1.018	-9%
Lymphoma	0.56%	<b>1.172</b>	1.043	-11%	<b>1.076</b>	-8%	1.039	-11%	1.041	-11%
Multiple Myeloma	0.51%	<b>1.188</b>	1.025	-14%	<b>1.082</b>	-9%	1.018	-14%	1.020	-14%
Leukemia	0.43%	<b>1.176</b>	1.014	-14%	<b>1.081</b>	-8%	1.004	-15%	1.022	-13%
Lymphatic & Major Cancers	0.04%	<b>1.095</b>	1.033	-6%	1.032	-6%	1.036	-5%	1.028	-6%

**Table 2B: Models 1 - 5: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier									
		Model 1	Model 2	Model 3	Model 4	Model 5					
<b>Model parameters</b>											
Model form		Log	Log	Log	Log	Log	Log	Log	Log	Log	
Base CM model		X	X	X	X	X	X	X	X	X	
EPO Response (1 to 3 months)			X				X		X		
EPO Response (6 to 8 months)				X							
Hct (prior month)							X				
Facility										X	
Hyperparathyroidism	13.50%	1.008	1.010	0%	1.010	0%	1.012	0%	1.022	1%	
Myelodysplastic Syndrome	1.17%	<b>1.377</b>	1.047	-24%	<b>1.136</b>	-17%	1.034	-25%	1.045	-24%	
Monoclonal Gammopathy	0.66%	<b>1.090</b>	1.011	-7%	1.042	-4%	1.009	-7%	1.014	-7%	
Myelofibrosis	0.03%	<b>1.215</b>	<b>1.107</b>	-9%	<b>1.163</b>	-4%	<b>1.099</b>	-10%	<b>1.117</b>	-8%	
<b>Prior health care utilization</b>											
Prior month hospitalization	17.27%	<b>1.560</b>	<b>1.207</b>	-23%	<b>1.311</b>	-16%	<b>1.148</b>	-26%	<b>1.205</b>	-23%	
<b>Notes</b>											
* See Note 1.											
** See Note 4.											

**Table 3A: Case Mix Models 6 to 13**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Model							
	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model form	Log	Linear						
Reduced base CM model	X			X	X	X	X	X
Vintage	X		X	X	X	X	X	X
Prior EPO Response (1 to 3 months)**								
Prior EPO Response (6 to 8 months)**		X	X	X	X	X	X	X
Hct (prior month)					X		X	
Facility						X	X	
Patient months	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012
Percent of total used in analysis	79%	79%	79%	79%	79%	79%	79%	79%
R-squared	0.0690	0.2420	0.2416	0.2790	0.3703	0.3349	0.4564	0.2494
Mean (Actual)	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37
Std. Dev. Predicted	\$21.43	\$40.14	\$40.10	\$43.10	\$49.65	\$47.22	\$55.12	\$40.75
Std. Dev. Actual	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59
Correlation with prior month prediction error								
t-1	0.73	0.68	0.68	0.66	0.64	0.63	0.60	0.65
t-2	0.63	0.51	0.51	0.49	0.50	0.46	0.45	0.49
t-3	0.57	0.39	0.39	0.38	0.39	0.34	0.33	0.38
t-4	0.53	0.29	0.30	0.29	0.29	0.25	0.23	0.30
t-5	0.51	0.20	0.21	0.21	0.22	0.16	0.16	0.22
t-6	0.49	0.10	0.11	0.12	0.14	0.07	0.08	0.13
t-7	0.46	0.06	0.07	0.08	0.11	0.03	0.06	0.09
t-8	0.44	0.06	0.08	0.08	0.12	0.04	0.07	0.09
t-9	0.43	0.11	0.12	0.13	0.15	0.08	0.11	0.14
t-10	0.41	0.12	0.13	0.13	0.15	0.08	0.10	0.14
t-11	0.39	0.12	0.13	0.13	0.14	0.08	0.10	0.14

**Table 3A: Case Mix Models 6 to 13**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Model								
	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13	
Model form	Log	Log	Log	Log	Log	Log	Log	Linear	
Reduced base CM model	X			X	X	X	X	X	
Vintage	X		X	X	X	X	X	X	
Prior EPO Response (1 to 3 months)**									
Prior EPO Response (6 to 8 months)**		X	X	X	X	X	X	X	
Hct (prior month)					X		X		
Facility						X	X		
Percentile distribution of prediction error***									
Std Dev	\$78.13	\$74.04	\$73.24	\$71.75	\$69.74	\$69.42	\$67.25	\$70.69	
Minimum	-\$325.32	-\$384.95	-\$381.38	-\$775.15	-\$1,258.67	-\$900.92	-\$2,385.48	-\$335.44	
1st	-\$80.89	-\$106.62	-\$104.38	-\$108.01	-\$109.39	-\$110.96	-\$114.39	-\$122.00	
5th	-\$56.31	-\$56.23	-\$56.51	-\$56.89	-\$55.95	-\$56.90	-\$55.90	-\$79.65	
25th	-\$24.71	-\$22.44	-\$21.93	-\$21.13	-\$20.19	-\$20.36	-\$19.15	-\$37.32	
50th	\$4.30	\$5.45	\$5.55	\$5.41	\$5.51	\$4.61	\$4.74	-\$10.49	
75th	\$46.42	\$45.15	\$44.18	\$42.33	\$40.20	\$39.48	\$36.89	\$24.52	
95th	\$153.84	\$138.64	\$136.90	\$131.22	\$122.77	\$124.52	\$114.10	\$111.06	
99th	\$290.89	\$253.08	\$251.73	\$244.63	\$230.96	\$232.12	\$215.37	\$225.99	
Maximum	\$6,933.93	\$6,912.76	\$6,914.19	\$6,915.36	\$6,933.36	\$6,814.10	\$6,848.64	\$6,884.72	

#### Notes

- \* See Note 1.  
 \*\* See Note 2.  
 \*\*\* See Note 3.

**Table 3B: Models 6 - 13: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

Model parameters	Freq.**	Multiplier							
		Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model form		Log	Linear						
Reduced base CM model		X			X	X	X	X	X
Vintage		X		X	X	X	X	X	X
EPO Response (1 to 3 months)									
EPO Response (6 to 8 months)			X	X	X	X	X	X	X
Hct (prior month)						X		X	
Facility							X	X	
<b>Independent Variables</b>									
Prior EPO dose-response			<b>1.328</b>	<b>1.330</b>	<b>1.292</b>	<b>1.279</b>	<b>1.274</b>	<b>1.258</b>	<b>1.309</b>
Hematocrit (prior month)						0.956		0.951	
<b>Socio-demographic</b>									
Age <18	0.11%	0.971			<b>0.940</b>	<b>0.911</b>	<b>1.213</b>	<b>1.183</b>	<b>1.079</b>
Female	47.53%	<b>1.118</b>			<b>1.081</b>	<b>1.078</b>	<b>1.085</b>	<b>1.082</b>	1.043
Black	36.96%	<b>1.182</b>			<b>1.151</b>	<b>1.149</b>	<b>1.105</b>	<b>1.102</b>	<b>1.108</b>
Pacific Islander	0.84%	<b>0.915</b>			<b>0.928</b>	<b>0.925</b>	0.998	1.000	<b>0.940</b>
<b>Duration of RRT</b>									
Starting month	1.14%	<b>1.595</b>		<b>1.566</b>	<b>1.549</b>	<b>1.567</b>	<b>1.564</b>	<b>1.584</b>	<b>1.565</b>
Month 1	1.66%	<b>1.274</b>		<b>1.472</b>	<b>1.271</b>	<b>1.186</b>	<b>1.279</b>	<b>1.181</b>	<b>1.157</b>
Month 2	1.84%	<b>1.383</b>		<b>1.413</b>	<b>1.359</b>	<b>1.261</b>	<b>1.359</b>	<b>1.248</b>	<b>1.219</b>
Month 3	2.24%	<b>1.273</b>		<b>1.231</b>	<b>1.240</b>	<b>1.238</b>	<b>1.243</b>	<b>1.239</b>	<b>1.159</b>
Month 4	2.11%	<b>1.156</b>		<b>1.121</b>	<b>1.127</b>	<b>1.176</b>	<b>1.129</b>	<b>1.184</b>	<b>1.078</b>
Month 5	2.13%	<b>1.098</b>		<b>1.066</b>	<b>1.071</b>	<b>1.129</b>	<b>1.074</b>	<b>1.139</b>	1.030
Month 6	2.00%	<b>1.080</b>		0.984	0.996	1.037	1.002	1.049	<b>0.941</b>
Month 7	2.02%	<b>1.061</b>		<b>0.931</b>	<b>0.949</b>	0.980	0.955	0.991	<b>0.893</b>
Month 8	1.93%	1.023		<b>0.901</b>	<b>0.920</b>	<b>0.949</b>	<b>0.926</b>	0.960	<b>0.874</b>
Month 9	1.87%	0.999		<b>0.889</b>	<b>0.906</b>	<b>0.934</b>	<b>0.912</b>	<b>0.944</b>	<b>0.860</b>
Months 10-12	5.52%	0.983		<b>0.927</b>	<b>0.942</b>	0.959	<b>0.944</b>	0.965	<b>0.913</b>

**Table 3B: Models 6 - 13: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier							
		Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
<b>Model parameters</b>									
Model form		Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model		X			X	X	X	X	X
Vintage		X		X	X	X	X	X	X
EPO Response (1 to 3 months)									
EPO Response (6 to 8 months)			X	X	X	X	X	X	X
Hct (prior month)						X		X	
Facility							X	X	
<b>Laboratory values</b>									
Hematocrit at start of RRT		0.986			0.992	0.993	0.991	0.993	0.993
<b>Body size measures***</b>									
Body surface area		<b>1.391</b>			<b>1.221</b>	<b>1.212</b>	<b>1.241</b>	<b>1.229</b>	<b>1.187</b>
Body mass index < 18.5		1.005			0.995	0.991	1.000	0.996	1.011
<b>Comorbid Conditions****</b>									
Cardiac Arrest	1.58%	<b>1.133</b>			<b>1.065</b>	<b>1.057</b>	<b>1.062</b>	<b>1.054</b>	<b>1.079</b>
Pericarditis	1.23%	<b>1.184</b>			<b>1.072</b>	<b>1.065</b>	<b>1.066</b>	<b>1.058</b>	<b>1.087</b>
Septicemia/Shock	12.44%	<b>1.149</b>			<b>1.101</b>	<b>1.095</b>	<b>1.103</b>	<b>1.098</b>	<b>1.100</b>
Aspir. & Bact. Pneumonias	1.99%	<b>1.108</b>			<b>1.077</b>	<b>1.068</b>	<b>1.073</b>	<b>1.062</b>	<b>1.095</b>
Major respiratory disease	1.28%	<b>1.135</b>			<b>1.089</b>	<b>1.081</b>	<b>1.086</b>	<b>1.077</b>	<b>1.088</b>
Opportunistic Infections	0.67%	<b>1.200</b>			<b>1.115</b>	<b>1.093</b>	<b>1.119</b>	<b>1.096</b>	<b>1.155</b>
GI Ulcer - no hemorrhage	3.13%	<b>1.111</b>			<b>1.076</b>	<b>1.071</b>	<b>1.076</b>	<b>1.071</b>	<b>1.074</b>
GI Tract Bleeding	1.99%	<b>1.187</b>			<b>1.138</b>	<b>1.122</b>	<b>1.134</b>	<b>1.115</b>	<b>1.141</b>
Sickle-Cell Anemia	0.37%	<b>1.214</b>			<b>1.063</b>	1.040	<b>1.078</b>	<b>1.052</b>	<b>1.117</b>
Esophageal Varices	0.19%	<b>1.297</b>			<b>1.137</b>	<b>1.093</b>	<b>1.155</b>	<b>1.106</b>	<b>1.196</b>

**Table 3B: Models 6 - 13: Independent Variable Coefficients**  
**Bundle 1C payment per session**  
**HD Patients, 2003 (N=1,943,552 months)\***

	Freq.**	Multiplier							
		Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
<b>Model parameters</b>									
Model form		Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model		X			X	X	X	X	X
Vintage		X		X	X	X	X	X	X
EPO Response (1 to 3 months)									
EPO Response (6 to 8 months)			X	X	X	X	X	X	X
Hct (prior month)						X		X	
Facility							X	X	
Breast & Other Cancers	5.81%	<b>1.079</b>			<b>1.055</b>	<b>1.053</b>	1.049	1.046	1.044
Metastatic Cancers	1.09%	<b>1.131</b>			<b>1.068</b>	<b>1.057</b>	<b>1.066</b>	<b>1.055</b>	<b>1.088</b>
Lung & Severe Cancers	1.02%	<b>1.111</b>			<b>1.060</b>	<b>1.051</b>	<b>1.056</b>	1.046	<b>1.077</b>
Lymphoma	0.56%	<b>1.160</b>			<b>1.082</b>	<b>1.071</b>	<b>1.082</b>	<b>1.071</b>	<b>1.103</b>
Multiple Myeloma	0.51%	<b>1.166</b>			<b>1.091</b>	<b>1.077</b>	<b>1.087</b>	<b>1.071</b>	<b>1.129</b>
Leukemia	0.43%	<b>1.159</b>			<b>1.085</b>	<b>1.064</b>	<b>1.095</b>	<b>1.071</b>	<b>1.142</b>
Myelodysplastic Syndrome	1.17%	<b>1.291</b>			<b>1.133</b>	<b>1.105</b>	<b>1.131</b>	<b>1.098</b>	<b>1.165</b>
Myelofibrosis	0.03%	<b>1.263</b>			<b>1.186</b>	<b>1.173</b>	<b>1.200</b>	<b>1.189</b>	<b>1.226</b>
<b>Prior health care utilization</b>									
Prior month hospitalization	17.27%	<b>1.387</b>			<b>1.320</b>	<b>1.227</b>	<b>1.312</b>	<b>1.207</b>	<b>1.276</b>
<b>Notes</b>									
* See Note 1.									
** See Note 4.									
*** See Note 5.									
**** See Note 6.									

---

**Notes**

---

- Note 1. Includes patient months with 1-20 Medicare hemodialysis-equivalent dialysis sessions. Excludes patient months with missing data for one or more patient characteristics.
- Note 2. EPO response measures were calculated as the average EPO divided by the average HCT over a three month period ending 1-3 or 6-8 months prior to the current record.
- Note 3. These columns show the percent of patient months having prediction errors that are less than or equal to the dollar amount shown.
- Note 4. From May case mix models. Provided as a rough indicator of prevalence.
- Note 5. Body surface area (DuBois): per 0.1 m<sup>2</sup>  
Body mass index (kg/m<sup>2</sup>)
- Note 6. The more specific description of selected comorbid conditions is as follows:  
Cardiac Arrest within 12 months  
Pericarditis within 12 months  
Septicemia/Shock within 6 months  
Aspir. & Bact. Pneumonias: aspiration and specified bacterial pneumonias within 6 months  
Major respiratory disease: pneumococcal pneumonia, emphysema, lung abscess within 6 months  
Opportunistic Infections within 6 months  
GI Ulcer - no hemorrhage within 6 months  
GI Tract Bleeding within 6 months  
Sickle-Cell Anemia from 1999 to present  
Esophageal Varices within 6 months  
Breast & Other Cancers: Breast, prostate, colorectal and other cancers within 12 months  
Metastatic Cancers within 12 months  
Lung & Severe Cancers: lung, upper digestive tract, and other severe cancers within 12 months  
Lymphoma within 2 years  
Multiple Myeloma within 12 months  
Leukemia within 12 months  
Myelodysplastic Syndrome from 1999 to present  
Myelofibrosis within 12 months